Solid Organ Transplant Immunosuppressant Market to 2018 - Limited Availability of Donors Drives Improvements in Organ Procurement and Preservation Methods

Solid Organ Transplant Immunosuppressant Market to 2018 - Limited Availability of Donors Drives Improvements in Organ Procurement and Preservation Methods

Summary

GBI Research, the leading business intelligence provider, has released its latest research, “Solid Organ Transplant Immunosuppressant Market to 2018 - Limited Availability of Donors Drives Improvements in Organ Procurement and Preservation Methods”, which provides insight into the global solid organ transplant immunosuppressant drug market until 2018. The report provides an in-depth analysis of the following five transplant areas: heart, lung, pancreas, liver and kidney. It also details immunosuppressant drug markets in the following key regions: the US, the top five countries of Europe and Japan. The report also includes details about immunosuppressant drug R&D pipelines.

The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research’s team of industry experts.

GBI Research analysis shows that the global market for immunosuppressant drugs used in transplants is projected to increase at a compound annual growth rate (CAGR) of 6.7% from 2004–2010. The market is forecast to grow at a CAGR of 6.1% from 2010–2018, to reach a value of $5.6 billion in 2018. GBI Research analysis found the R&D pipeline for the immunosuppressant drug market to be moderate. The leading companies in this market, F. Hoffman La Roche, Novartis AG, Genzyme Corporation and Astellas Pharma Inc., are also analyzed in this report.

Scope

- Analysis of the five major solid organ immunosuppressant drugs market which include heart transplant, pancreas transplant, lung transplant, kidney transplant and liver transplant immunosuppressant drug market
- Data and analysis of the immunosuppressant drug market in the leading regions of the world: the US, the top five countries of Europe and Japan.
- Annualized market data for the immunosuppressant drug market from 2004–2010, with forecasts to 2018.
- Market data on the geographical landscape and therapeutic landscape, including market sizes, market shares, annual costs of therapy and target populations.
- Key drivers and restraints that have had a significant impact on the market.
- Pipeline analysis of the immunosuppressant drug market for the five types of transplant.
- Competitive landscape of the global immunosuppressant drug market including benchmarking of top companies. The key companies studied in this report are: F. Hoffman La Roche, Novartis AG, Genzyme Corporation and Astellas Pharma Inc.

Reasons to buy

- The report will aid business development and help marketing executives strategize product launches, and
- Build effective strategies to launch pipeline products by identifying potential geographies.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Develop market entry and market expansion strategies by identifying geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with better efficacy and safety.

Global Blood Supply, Tissue Banking And Transplantation Industry

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 6
1.2 List of Figures 9
2 Solid Organ Transplant Immunosuppressant Market to 2018 - Introduction 11
2.1 Overview 11
2.2 GBI Research Report Guidance 11
3 Solid Organ Transplant Immunosuppressant Market to 2018 - Market Overview 12
3.1 Introduction 12
3.1.1 Types of Transplant 12
3.1.2 Transplant Rejection 13
3.1.3 Immunosuppressive Drug Therapy 13
3.2 Market Forecast 15
3.2.1 Market Share by Disease Sector 16
3.2.2 Market Share by Geography 17
3.3 Annual Cost of Therapy 18
3.4 Target Population 19
3.5 Solid Organ Transplant Immunosuppressant Market Drivers and Restraints 20
3.5.1 Drivers 20
3.5.2 Restraints 21
4 Solid Organ Transplant Immunosuppressant Market to 2018 - Geographical Landscape 22
4.1 The US 22
4.1.1 Introduction 22
4.1.2 Revenue 22
4.1.3 Annual Cost of Therapy 23
4.1.4 Target Population 24
4.2 Top Five Countries of Europe 25
4.2.1 Introduction 25
4.2.2 Revenue 25
4.2.3 Annual Cost of Therapy 27
4.2.4 Target Population 28
4.3 Japan 29
4.3.1 Introduction 29
4.3.2 Revenue 29
4.3.3 Annual Cost of Therapy 30
4.3.4 Target Population 31
5 Solid Organ Transplant Immunosuppressant Market to 2018 - Therapeutic Landscape 33
5.1 Heart Transplant Market 33
5.1.1 Introduction 33
5.1.2 Revenue 33
5.1.3 Annual Cost of Therapy 34
5.1.4 Target Population 35
5.2 Lung Transplant Market 36
5.2.1 Introduction 36
5.2.2 Revenue 36
5.2.3 Annual Cost of Therapy 38
5.2.4 Target Population 39
5.3 Kidney Transplant Market 40
5.3.1 Introduction 40
5.3.2 Revenue 40
5.3.3 Annual Cost of Therapy 41
5.3.4 Target Population 42
5.4 Liver Transplant Market 43
5.4.1 Introduction 43
5.4.2 Revenue 43
5.4.3 Annual Cost of Therapy 45
5.4.4 Target Population 46
5.5 Pancreas Transplant Market 47
5.5.1 Introduction 47
5.5.2 Revenue 47
5.5.3 Annual Cost of Therapy 49
5.5.4 Target Population 50
6 Solid Organ Transplant Immunosuppressant Market to 2018 - Product Pipeline Analysis 51
6.1 Research and Development (R&D) Pipeline by Indication 51
6.2 R&D Pipeline by Phase 52
6.3 R&D Pipeline - Heart Transplant 53
6.3.1 Overview 53
6.3.2 Pre-Clinical Phase 54
6.3.3 Phase II 54
6.3.4 Phase III 54
6.4 R&D Pipeline - Lung Transplant 55
6.4.1 Overview 55
6.4.2 Pre-Clinical Phase 56
6.4.3 Phase II 56
6.4.4 Phase III 56
6.5 R&D Pipeline - Kidney Transplant 57
6.5.1 Overview 57
6.5.2 Pre-Clinical Phase 58
6.5.3 Phase I 58
6.5.4 Phase II 58
6.5.5 Phase III 59
6.6 R&D Pipeline - Liver Transplant 60
6.6.1 Overview 60
6.6.2 Pre-Clinical Phase 60
6.6.3 Phase II 61
6.6.4 Phase I 61
6.6.5 Pre-Clinical Phase 61
6.7 R&D Pipeline - Pancreas Transplant 62
6.7.1 Overview 62
6.7.2 Phase II 63
6.7.3 Phase III 63
7 Solid Organ Transplant Immunosuppressant Market to 2018 - Marketed Products 64
7.1 Prograf 64
7.1.1 Overview 64
7.1.2 Safety 64
7.1.3 Efficacy 64
7.2 Cellcept 65
7.2.1 Overview 65
7.2.2 Safety 65
7.2.3 Efficacy 65
7.3 Myfortic 66
7.3.1 Overview 66
7.3.2 Safety 66
7.3.3 Efficacy 67
7.4 Neoral 67
7.4.1 Overview 67
7.4.2 Safety 67
7.4.3 Efficacy 67
7.5 Zenapax 68
7.5.1 Overview 68
7.5.2 Safety 68
7.5.3 Efficacy 68
8 Solid Organ Transplant Immunosuppressant Market to 2018 - Competitive Landscape 69
8.1 F. Hoffman La Roche 69
8.1.1 Overview 69
8.1.2 Marketed Products 69
8.1.3 SWOT Analysis 70
8.2 Novartis AG 71
8.2.1 Overview 71
8.2.2 Marketed Products 71
8.2.3 SWOT Analysis 72
8.3 Genzyme Corporation 72
8.3.1 Overview 72
8.3.2 Marketed Products 72
8.3.3 SWOT Analysis 73
8.4 Astellas Pharma Inc. 73
8.4.1 Overview 73
8.4.2 Marketed Products 73
8.4.3 SWOT Analysis 74
9 Solid Organ Transplant Immunosuppressant Market to 2018 - Strategic Consolidations 75
9.1 Segmentation by Type 75
9.2 Segmentation by Year 76
9.3 Segmentation by Indication 77
9.4 Segmentation by Geography 78
9.5 Segmentation by Deal Value 79
9.6 Major M&As 80
9.7 Major Licensing Agreements 80
9.8 Major Co-Development Deals 81
10 Solid Organ Transplant Immunosuppressant Market to 2018 -Appendix 82
10.1 Market Definitions 82
10.2 Abbreviations 82
10.3 Research Methodology 82
10.3.1 Coverage 82
10.3.2 Secondary Research 83
10.3.3 Primary Research 83
10.3.4 Therapeutic Landscape 83
10.3.5 Market Size by Geography 85
10.3.6 Geographical Landscape 86
10.3.7 Pipeline Analysis 86
10.3.8 Competitive Landscape 86
10.3.9 Expert Panel Validation 86
10.4 Contact Us 86
10.5 Disclaimer 86
10.6 Sources 87

1.1 List of Tables

Table 1: Solid Organ Transplant Immunosuppressant Market, Global, Revenue ($bn), 2004-2010 15
Table 2: Solid Organ Transplant Immunosuppressant Market, Global, Revenue Forecast ($bn), 2010-2018 15
Table 3: Solid Organ Transplant Immunosuppressant Market, Global, Annual Cost of Therapy ($), 2004-2010 18
Table 4: Solid Organ Transplant Immunosuppressant Market, Global, Annual Cost of Therapy ($), 2010-2018 18
Table 5: Solid Organ Transplant Immunosuppressant Market, Global, Target Population, 2004-2010 19
Table 6: Solid Organ Transplant Immunosuppressant Market, Global, Target Population, 2010-2018 19
Table 7: Solid Organ Transplant Immunosuppressant Market, The US, Revenue ($bn), 2004-2010 22
Table 8: Solid Organ Transplant Immunosuppressant Market, The US, Revenue Forecast ($bn), 2010-2018 23
Table 9: Solid Organ Transplant Immunosuppressant Market, The US, Annual Cost of Therapy ($), 2004-2010 23
Table 10: Solid Organ Transplant Immunosuppressant Market, The US, Annual Cost of Therapy ($), 2010-2018 24
Table 11: Solid Organ Transplant Immunosuppressant Market, The US, Target Population, 2004-2010 24
Table 12: Solid Organ Transplant Immunosuppressant Market, The US, Target Population, 2010-2018 25
Table 13: Solid Organ Transplant Immunosuppressant Market, Top Five Countries of Europe, Revenue ($m), 2004-2010 26
Table 14: Solid Organ Transplant Immunosuppressant Market, Top Five Countries of Europe, Revenue Forecast ($m), 2010-2018 26
Table 15: Solid Organ Transplant Immunosuppressant Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2004-2010 27
Table 16: Solid Organ Transplant Immunosuppressant Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2010-2018 27
Table 17: Solid Organ Transplant Immunosuppressant Market, Top Five Countries of Europe, Target Population, 2004-2010 28
Table 18: Solid Organ Transplant Immunosuppressant Market, Top Five Countries of Europe, Target Population, 2010-2018 28
Table 19: Solid Organ Transplant Immunosuppressant Market, Japan, Revenue ($m), 2004-2010 29
Table 20: Solid Organ Transplant Immunosuppressant Market, Japan, Revenue Forecast ($m), 2010-2018 30
Table 21: Solid Organ Transplant Immunosuppressant Market, Japan, Annual Cost of Therapy ($), 2004-2010 30
Table 22: Solid Organ Transplant Immunosuppressant Market, Japan, Annual Cost of Therapy ($), 2010-2018 31
Table 23: Solid Organ Transplant Immunosuppressant Market, Japan, Target Population, 2004-2010 31
Table 24: Solid Organ Transplant Immunosuppressant Market, Japan, Target Population, 2010-2018 32
Table 25: Heart Transplant Immunosuppressant Market, Global, Revenue ($m), 2004-2010 33
Table 26: Heart Transplant Immunosuppressant Market, Global, Revenue Forecast ($m), 2010-2018 34
Table 27: Heart Transplant Immunosuppressant Market, Global, Annual Cost of Therapy ($), 2004-2010 34
Table 28: Heart Transplant Immunosuppressant Market, Global, Annual Cost of Therapy ($), 2010-2018 34
Table 29: Heart Transplant Immunosuppressant Market, Global, Target Population, 2004-2010 35
Table 30: Heart Transplant Immunosuppressant Market, Global, Target Population, 2010-2018 35
Table 31: Lung Transplant Immunosuppressant Market, Global, Revenue ($m), 2004-2010 37
Table 32: Lung Transplant Immunosuppressant Market, Global, Revenue Forecast ($m), 2010-2018 37
Table 33: Lung Transplant Immunosuppressant Market, Global, Annual Cost of Therapy ($), 2004-2010 38
Table 34: Lung Transplant Immunosuppressant Market, Global, Annual Cost of Therapy ($), 2010-2018 38
Table 35: Lung Transplant Immunosuppressant Market, Global, Target Population, 2004-2010 39
Table 36: Lung Transplant Immunosuppressant Market, Global, Target Population, 2010-2018 39
Table 37: Kidney Transplant Immunosuppressant Market, Global, Revenue ($bn), 2004-2010 40
Table 38: Kidney Transplant Immunosuppressant Market, Global, Revenue Forecast ($bn), 2010-2018 41
Table 39: Kidney Transplant Immunosuppressant Market, Global, Annual Cost of Therapy ($), 2004-2010 41
Table 40: Kidney Transplant Immunosuppressant Market, Global, Annual Cost of Therapy ($), 2010-2018 42
Table 41: Kidney Transplant Immunosuppressant Market, Global, Target Population, 2004-2010 42
Table 42: Kidney Transplant Immunosuppressant Market, Global, Target Population, 2010-2018 43
Table 43: Liver Transplant Immunosuppressant Market, Global, Revenue ($m), 2004-2010 44
Table 44: Liver Transplant Immunosuppressant Market, Global, Revenue Forecast ($m), 2010-2018 44
Table 45: Liver Transplant Immunosuppressant Market, Global, Annual Cost of Therapy ($), 2004-2010 45
Table 46: Liver Transplant Immunosuppressant Market, Global, Annual Cost of Therapy ($), 2010-2018 45
Table 47: Liver Transplant Immunosuppressant Market, Global, Target Population, 2004-2010 46
Table 48: Liver Transplant Immunosuppressant Market, Global, Target Population, 2010-2018 46
Table 49: Pancreas Transplant Immunosuppressant Market, Global, Revenue ($m), 2004-2010 48
Table 50: Pancreas Transplant Immunosuppressant Market, Global, Revenue Forecast ($m), 2010-2018 48
Table 51: Pancreas Transplant Immunosuppressant Market, Global, ANNUAL COST OF THERAPY ($), 2004-2010 49
Table 52: Pancreas Transplant Immunosuppressant Market, Global, ANNUAL COST OF THERAPY ($), 2010-2018 49
Table 53: Pancreas Transplant Immunosuppressant Market, Global, Target Population, 2004-2010 50
Table 54: Pancreas Transplant Immunosuppressant Market, Global, Target Population, 2010-2018 50
Table 55: Solid Organ Transplant Immunosuppressant Market, Global, Pipeline Molecules by Indication (%), 2011 51
Table 56: Solid Organ Transplant Immunosuppressant Market, Global, Pipeline Molecules by Phase (%), 2011 52
Table 57: Heart Transplant Immunosuppressant Market, Global, Pipeline Molecules by Phase (%), 2011 53
Table 58: Heart Transplant Immunosuppressant Market, Global, Pre-Clinical Pipeline Molecules, 2011 54
Table 59: Heart Transplant Immunosuppressant Market, Global, Phase II Pipeline Molecules, 2011 54
Table 60: Heart Transplant Immunosuppressant Market, Global, Phase III Pipeline Molecules, 2011 54
Table 61: Lung Transplant Immunosuppressant Market, Global, Pipeline Molecules by Phase (%), 2011 55
Table 62: Lung Transplant Immunosuppressant Market, Global, Pre-Clinical Pipeline Molecules, 2011 56
Table 63: Lung Transplant Immunosuppressant Market, Global, Phase II Pipeline Molecules, 2011 56
Table 64: Lung Transplant Immunosuppressant Market, Global, Phase III Pipeline Molecules, 2011 56
Table 65: Kidney Transplant Immunosuppressant Market, Global, Pipeline Molecules by Phase (%), 2011 57
Table 66: Kidney Transplant Immunosuppressant Market, Global, Pre-Clinical Pipeline Molecules, 2011 58
Table 67: Kidney Transplant Immunosuppressant Market, Global, Phase I Pipeline Molecules, 2011 58
Table 68: Kidney Transplant Immunosuppressant Market, Global, Phase II Pipeline Molecules, 2011 58
Table 69: Kidney Transplant Immunosuppressant Market, Global, Phase III Pipeline Molecules, 2011 59
Table 70: Liver Transplant Immunosuppressant Market, Global, Pipeline Molecules by Phase (%), 2011 60
Table 71: Liver Transplant Immunosuppressant Market, Global, Pre-Clinical Pipeline Molecules, 2011 60
Table 72: Liver Transplant Immunosuppressant Market, Global, Phase I Pipeline Molecules, 2011 61
Table 73: Liver Transplant Immunosuppressant Market, Global, Phase II Pipeline Molecules, 2011 61
Table 74: Liver Transplant Immunosuppressant Market, Global, Phase III Pipeline Molecules, 2011 61
Table 75: Pancreas Transplant Immunosuppressant Market, Global, Pipeline Molecules by Phase (%), 2011 62
Table 76: Pancreas Transplant Immunosuppressant Market, Global, Phase II Pipeline Molecules, 2011 63
Table 77: Pancreas Transplant Immunosuppressant Market, Global, Phase II Pipeline Molecules, 2011 63
Table 78: Solid Organ Transplant Immunosuppressant Market, Marketed Products, F. Hoffman La Roche, 2011 69
Table 79: Solid Organ Transplant Immunosuppressant Market, Marketed Products, Novartis AG, 2011 71
Table 80: Solid Organ Transplant Immunosuppressant Market, Marketed Products, F. Genzyme Corporation, 2011 72
Table 81: Solid Organ Transplant Immunosuppressant Market, Marketed Products, Astellas Pharma Inc., 2011 73
Table 82: Solid Organ Transplant Immunosuppressant Market, Global, Deals by Type (%), 2004-2011 75
Table 83: Solid Organ Transplant Immunosuppressant Market, Global, Deals by Year, 2004-2011 76
Table 84: Solid Organ Transplant Immunosuppressant Market, Global, Deals by Indication, 2004-2011 77
Table 85: Solid Organ Transplant Immunosuppressant Market, Global, Deals by Geography, 2004-2011 78
Table 86: Solid Organ Transplant Immunosuppressant Market, Global, Deals by Value (million), 2004-2011 79
Table 87: Solid Organ Transplant Immunosuppressant Market, Global, Major M&A Deals, 2011 80
Table 88: Solid Organ Transplant Immunosuppressant Market, Global, Major Licensing Deals, 2009-2011 80
Table 89: Solid Organ Transplant Immunosuppressant Market, Global, Major Co-Development Deals, 2009-2011 81

1.2 List of Figures

Figure 1: Solid Organ Transplant Immunosuppressant Market, Types of Transplant, 2011 12
Figure 2: Solid Organ Transplant Immunosuppressant Market, Classification of Immunosuppressant Drugs, 2011 13
Figure 3: Solid Organ Transplant Immunosuppressant Market, Immunosuppressant Drug Monitoring, 2011 14
Figure 4: Solid Organ Transplant Immunosuppressant Market, Global, Revenue Forecast ($bn), 2004-2018 15
Figure 5: Solid Organ Transplant Immunosuppressant Market, Global, Market Share by Disease Segment, 2010 16
Figure 6: Solid Organ Transplant Immunosuppressant Market, Global, Market Share by Geography, 2010 17
Figure 7: Solid Organ Transplant Immunosuppressant Market, Global, Annual Cost of Therapy ($), 2004-2018 18
Figure 8: Solid Organ Transplant Immunosuppressant Market, Global, Target Population, 2004-2018 19
Figure 9: Solid Organ Transplant Immunosuppressant Market, Drivers and Restraints, 2011 20
Figure 10: Solid Organ Transplant Immunosuppressant Market, The US, Revenue Forecast ($bn), 2004-2018 22
Figure 11: Solid Organ Transplant Immunosuppressant Market, The US, Annual Cost of Therapy ($), 2004-2018 23
Figure 12: Solid Organ Transplant Immunosuppressant Market, The US, Target Population, 2004-2018 24
Figure 13: Solid Organ Transplant Immunosuppressant Market, Top Five Countries of Europe, Revenue Forecast ($m), 2004-2018 25
Figure 14: Solid Organ Transplant Immunosuppressant Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2004-2018 27
Figure 15: Solid Organ Transplant Immunosuppressant Market, Top Five Countries of Europe, Target Population, 2004-2018 28
Figure 16: Solid Organ Transplant Immunosuppressant Market, Japan, Revenue Forecast ($m), 2004-2018 29
Figure 17: Solid Organ Transplant Immunosuppressant Market, Japan, Annual Cost of Therapy ($), 2004-2018 30
Figure 18: Solid Organ Transplant Immunosuppressant Market, Japan, Target Population, 2004-2018 31
Figure 19: Heart Transplant Immunosuppressant Market, Global, Revenue Forecast ($m), 2004-2018 33
Figure 20: Heart Transplant Immunosuppressant Market, Global, Annual Cost of Therapy ($), 2004-2018 34
Figure 21: Heart Transplant Immunosuppressant Market, Global, Target Population, 2004-2018 35
Figure 22: Lung Transplant Immunosuppressant Market, Global, Revenue Forecast ($m), 2004-2018 36
Figure 23: Lung Transplant Immunosuppressant Market, Global, Annual Cost of Therapy ($), 2004-2018 38
Figure 24: Lung Transplant Immunosuppressant Market, Global, Target Population, 2004-2018 39
Figure 25: Kidney Transplant Immunosuppressant Market, Global, Revenue Forecast ($bn), 2004-2018 40
Figure 26: Kidney Transplant Immunosuppressant Market, Global, Annual Cost of Therapy ($), 2004-2018 41
Figure 27: Kidney Transplant Immunosuppressant Market, Global, Target Population, 2004-2018 42
Figure 28: Liver Transplant Immunosuppressant Market, Global, Revenue Forecast ($m), 2004-2018 43
Figure 29: Liver Transplant Immunosuppressant Market, Global, Annual Cost of Therapy ($), 2004-2018 45
Figure 30: Liver Transplant Immunosuppressant Market, Global, Target Population, 2004-2018 46
Figure 31: Pancreas Transplant Immunosuppressant Market, Global, Revenue Forecast ($m), 2004-2018 47
Figure 32: Pancreas Transplant Immunosuppressant Market, Global, Annual Cost of Therapy ($), 2004-2018 49
Figure 33: Pancreas Transplant Immunosuppressant Market, Global, Target Population, 2004-2018 50
Figure 34: Solid Organ Transplant Immunosuppressant Market, Global, Pipeline Molecules by Indication (%), 2011 51
Figure 35: Solid Organ Transplant Immunosuppressant Market, Global, Pipeline Molecules by Phase (%), 2011 52
Figure 36: Heart Transplant Immunosuppressant Market, Global, Pipeline Molecules by Phase (%), 2011 53
Figure 37: Lung Transplant Immunosuppressant Market, Global, Pipeline Molecules by Phase (%), 2011 55
Figure 38: Kidney Transplant Immunosuppressant Market, Global, Pipeline Molecules by Phase (%), 2011 57
Figure 39: Liver Transplant Immunosuppressant Market, Global, Pipeline Molecules by Phase (%), 2011 60
Figure 40: Pancreas Transplant Immunosuppressant Market, Global, Pipeline Molecules by Phase (%), 2011 62
Figure 41: Solid Organ Transplant Immunosuppressant Market, SWOT Analysis, F. Hoffman La Roche, 2011 70
Figure 42: Solid Organ Transplant Immunosuppressant Market, SWOT Analysis, Novartis AG, 2011 72
Figure 43: Solid Organ Transplant Immunosuppressant Market, SWOT Analysis, Genzyme Corporation, 2011 73
Figure 44: Solid Organ Transplant Immunosuppressant Market, SWOT Analysis, Astellas Pharma Inc., 2011 74
Figure 45: Solid Organ Transplant Immunosuppressant Market, Global, Deals by Type (%), 2004-2011 75
Figure 46: Solid Organ Transplant Immunosuppressant Market, Global, Deals by Year, 2004-2011 76
Figure 47: Solid Organ Transplant Immunosuppressant Market, Global, Deals by Indication, 2004-2011 77
Figure 48: Solid Organ Transplant Immunosuppressant Market, Global, Deals by Geography, 2004-2011 78
Figure 49: Solid Organ Transplant Immunosuppressant Market, Global, Deals by Value (million), 2004-2011 79
Figure 50: GBI Research Market Forecasting Model 85

Companies mentioned

F. Hoffman La Roche
Novartis AG
Genzyme Corporation
Astellas Pharma Inc.